title: Response to letter "Evaluations of activated clotting time technologies require understanding activating clotting time system differences" by Marcia L. Zucker.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Hannan
authors.forename: Jorge W
authors.initials: JW
authors.lastname: Ojito
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology*; D016903:Drug Monitoring / Q000295:instrumentation*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D019095:Point-of-Care Systems; D014914:Whole Blood Coagulation Time / Q000295:instrumentation*
chemical_list: D006493:Heparin